Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522076 | 0.87 | NOTUM (0.45) | CES2CES1SLC6A3CA12CA1 | |
| SCHEMBL7058435 | 0.84 | CA12 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15876054 | 0.83 | — | — | |
| SCHEMBL15875999 | 0.83 | SLC7A5 (0.44) | CES2CES1SLC6A3CA12CA1 | |
| SCHEMBL662974 | 0.82 | CES2 (0.50) | CES2CES1CA12CA1CA2 | |
| SCHEMBL4224819 | 0.81 | ESR1 (0.55) | CES2CES1SLC7A5MEN1LMNA | |
| SCHEMBL30437641 | 0.81 | ESR1 (0.55) | CES2CES1SLC7A5MEN1LMNA | |
| SCHEMBL24526871 | 0.81 | SLC7A5 (0.36) | CES2CES1SLC6A3CA12CA1 | |
| SCHEMBL663524 | 0.80 | SERPINE1 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30437614 | 0.80 | HCAR2 (0.55) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230101612-A1 | PREPARATION OF A P2X3 ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-03-30 | — | — | US | claimed |
| EP-4103572-A1 | PREPARATION OF A P2X3 ANTAGONIST | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | claimed |
| CN-115427419-A | Preparation of P2X3 antagonists | 贝卢斯医疗咳嗽病公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2021161109-A1 | PREPARATION OF A P2X3 ANTAGONIST | BELLUS HEALTH COUGH INC. (CA) | 2021-08-19 | — | — | WO | claimed |
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | disclosed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-12503470-B2 | Preparation of a P2X3 antagonist | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| WO-2024194352-A1 | DEUTERATED P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-26 | — | — | WO | disclosed |
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230101612-A1 | PREPARATION OF A P2X3 ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2396304-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | Exelixis, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011071565-A1 | TGR5 AGONISTS | EXELIXIS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010093845-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7119073-B2 | Peptides and their use as inhibitors of hepatitis C virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-10-10 | — | — | US | disclosed |
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-07-22 | — | — | US | disclosed |
| EP-1392721-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002079234-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | CTRL, VIP, CTSC | CES2 702/4885CES1 44/4885SLC6A3 3772/4885 |
| US-20230101612-A1 | PREPARATION OF A P2X3 ANTAGONIST | P2RX3, P2RX4, P2RX5 | CES2 3268/4885CES1 3629/4885SLC6A3 642/4885 |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | CES2 3840/4885CES1 2314/4885SLC6A3 151/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | CES2 3840/4885CES1 2314/4885SLC6A3 151/4885 |
| US-12503470-B2 | Preparation of a P2X3 antagonist | P2RX3, P2RX4, P2RX7 | CES2 3372/4885CES1 3417/4885SLC6A3 630/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | CES2 3840/4885CES1 2314/4885SLC6A3 151/4885 |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | CES2 1346/4885CES1 216/4885SLC6A3 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.